Table 3. Summary of outcomes of the selected studies.
| Reference, Year | Sample Size | Median follow-up (mo) | FFBF* (% or median) | PSA Nadir | Toxicity Measurement Method | Late Grade ≥3 GI Toxicity (%) | Late Grade ≥3 GU Toxicity (%) | QOL Conclusions |
|---|---|---|---|---|---|---|---|---|
| Quon, 2018 | 152 | 47 | NR | NR | RTOG | 4.07 | 9.4 | Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to treatment EOD. Patients should be counselled regarding the significant short-term benefits of a longer overall treatment time. |
| Boyer, 2017 | 60 | 27.6 | NR | NR | CTCAE | 1.7 | 0 | AUASS 11 during SBRT, and 5 at 5 mo EPIC 91.7 and 88.9 at 3 and 12 mo |
| Hannan, 2016 | 91 | 54 | 100% at 3y 98.6% at 5y | 0.13 | RTOG | 6.8 | 5.5 | No differences among dose levels for EPIC or AUASS |
| Rucinska, 2016 | 68 | 24 | 100% | 0.03 | RTOG | 0 | 0 | GHS/QoL was “good” 9 mo post-SBRT, significantly improved thereafter |
| Shikama, 2016 | 20 | 30 | 100% | 0.73 | CTCAE | 2.5 | 0 | NR |
| D’Agostino, 2016 | 90 | 28 | 97.8% at 27 mo | NR | CTCAE | 0 | 0 | NR |
| Bauman, 2015 | 15 | 6 | NR | 0.3 | CTCAE | 25 | 6.7% | NR |
| Bernetich, 2014 | 142 | 38 | 92.7% at 5 years for the entire cohort | 0.16 | RTOG | 0 | 2 | NR |
| Kim, 2014 | 91 | 42 | 99% | NR | CTCAE | 5.5 | NR | EPIC bowel scores lower than baseline 18 months post-SBRT |
| King, 2013 | 1100 | 36 | 93% | 0.51 | NR | NR | NR | Urinary and bowel QOL decline most notable within the first 3 mo, mostly recovered by 6 mo, stable thereafter, improvement over baseline starting at 3y |
| Loblaw, 2013 | 84 | 55 | 99.9% | NR | RTOG | 1 | 1 | No significant decline in long-term QOL |
| Alongi, 2013 | 40 | 11 | NR | 0.2 | CTCAE | 0 | 0 | NR |
| McBride, 2011 | 45 | 45 | NR | <1 | CTCAE | 0 | 2.5 | Significant late decline in SHIM and EPIC sexual scores, small, late decline in EPIC bowel domain |
| Madsen, 2007 | 40 | 41 | 90% | NR | CTCAE | 0 | 0 | NR |
Abbreviations: NR, not reported; FFBF, actuarial freedom from biochemical failure; PSA, prostate-specific antigen; GI, gastrointestinal; GU, genitourinary; QOL, quality of life; CTCAE, Common Toxicity Criteria for Adverse Events; AUASS; American Urologic Association Symptom Score; SBRT, stereotactic body radiation therapy; EPIC, Expanded Prostate Cancer Index; RTOG, Radiation Therapy Oncology Group; GHS, global health score; LR, low-risk; IR, intermediate-risk; HR, high-risk; SHIM, Sexual Health Inventory in Men.
*All studies but one utilized the Phoenix definition of biochemical failure.